Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verbist, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verbist, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 285-293
© 1996 The British Society for Antimicrobial Chemotherapy

research-article

Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients

L. Verbista, J. Verhaegena, Ch. Wountersb, G. Vandenhovenb and a Multicentre Study Group*

aClinical Bacteriology, University Hospital St Rafaël B-3000 Leuven bCyanamid Benelux, Rue du Bosquet 15 B-1348 Louvain-la-Neuve, Belgium

Received 27 June 1995; returned 25 August 1995; accepted 28 September 1995

The comparative activities of piperacillin/tazobactam and other antibiotics against 5625 Gram-negative and Gram-positive bactena freshly isolated from hospitalized patients was examined. The percentage of Enterobacteriaceae susceptible to piperacillin/tazobactam, ceftazidime, imipenem and ciprofloxacin was very similar and varied from 81% to 84% in the Enterobacteriaceae with inducible type 1 ß-lactamases and from 93 to 97% in the non-inducible organisms. Piperacillin/tazobactam was similar in activity to ceftazidime against Pseudomonas aeruginosa and more active than imipenem or ciprofloxacin.

Piperacillin/tazobactam is more active than ceftazidime against Gram-positive bacteria (staphylococci, enterococci) and seems to be a promising antibiotic for nosocomial infections.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. Van Eldere
Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections
J. Antimicrob. Chemother., February 1, 2003; 51(2): 347 - 352.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.